Johnson & Johnson Offers Up To $5.5B To Settle Baby Powder Lawsuits
Johnson & Johnson (J&J) has proposed a settlement of up to $5.5 billion to resolve most of the remaining U.S. lawsuits alleging that its talc-based baby powder caused ovarian cancer. The proposal covers about 69,000 lawsuits and marks a significant step toward ending one of the healthcare company’s longest-running legal battles. However, J&J continues to deny that its talc products caused cancer and says the settlement is intended to resolve legal claims rather than acknowledge liability.
The agreement will take effect only if legal firms representing 95% of the remaining ovarian cancer claimants in U.S. state and federal courts approve its terms. If that threshold is reached, the settlement could substantially reduce one of the largest product liability disputes in the healthcare industry. It would also allow Johnson & Johnson to move beyond years of legal uncertainty while enabling affected claimants to receive compensation through a structured resolution process.
How the Johnson & Johnson Baby Powder Lawsuits Began
The legal dispute began in 2009, when women across the United States alleged that long-term use of Johnson & Johnson’s talc-based baby powder had contributed to the development of ovarian cancer. As the number of claims grew over the following years, plaintiffs argued that the talc used in the products contained asbestos or became contaminated during mining. Because asbestos is a known carcinogen, they claimed prolonged exposure increased the risk of cancer. The rising number of lawsuits eventually turned the case into one of the largest product liability disputes involving a healthcare company.
Throughout the litigation, Johnson & Johnson has maintained that its talc products are safe, asbestos-free, and supported by scientific research. Despite defending its position in courts across the United States, the company faced years of costly legal proceedings and differing court rulings. In 2020, J&J stopped selling talc-based baby powder in the United States and later completed a global transition to a cornstarch-based formula, reflecting a major product change while the legal challenges continued.
What the $5.5 Billion Settlement Means and What Happens Next
The proposed settlement is intended to resolve nearly all remaining U.S. ovarian cancer lawsuits without requiring years of additional courtroom battles. The company says the settlement offers a practical way to conclude prolonged litigation, reduce future legal uncertainty, and focus on its core healthcare business. The agreement will proceed only after the required claimant support is secured.
Under the proposal, Johnson & Johnson plans to pay up to $3 billion in 2027, with no further payments scheduled before 2028. The settlement applies only to U.S. ovarian cancer claims and does not include the separate UK High Court product liability case involving more than 7,000 claimants. If approved, the agreement could bring one of the company’s most significant legal disputes close to an end, providing greater certainty for claimants while allowing Johnson & Johnson to move forward after more than a decade of litigation.
Web Resources On Johnson & Johnson baby powder lawsuit
1. BBC.com : Johnson & Johnson offers up to $5.5bn to settle US baby powder lawsuits.
2. Market Screener.com : Johnson & Johnson Agrees to Pay Up to $5.5 Billion to Settle Talc Lawsuits.
3. Guardian.com : Johnson & Johnson to pay $5.5bn settlement in talc cancer lawsuit.
4. Indian Express.com : Why Johnson & Johnson is paying $5.5 billion over baby powder lawsuits.